Vorapaxar in patients with peripheral artery disease: subgroup analysis of the TRA 2P-TIMI 50 study

Source: Circulation Area: News According to research reported early online in Circulation, the addition of vorapaxar to standard therapy for peripheral arterial disease (PAD) was not associated with a statistically significant reduction on the risk of cardiovascular death, MI or stroke. Although it reduced the incidence of acute limb ischaemia and peripheral revascularisation, it was associated with an increased risk of bleeding.   The authors note that patients with PAD are at an increased risk of acute thromboembolic events. Those without clinically manifest coronary or cerebrovascular disease will often have subclinical atherosclerosis which puts them at risk of adverse outcomes. Secondary preventative strategies in this population have been targeted primarily at the reduction of major cardiovascular outcomes. Although antiplatelet therapy has been used to reduce the risk of cardiovascular events in patients with PAD, the choice and intensity are debated and some studies have suggested no benefit of ...
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news